{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:59:37Z","timestamp":1777719577598,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 GM149213"],"award-info":[{"award-number":["R35 GM149213"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00044-026-03553-2","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T16:46:59Z","timestamp":1777135619000},"page":"834-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated 3D-QSAR and cellular profiling of sulfated and hydrophobic aminoglycoside glycans to modulate heparanase activity"],"prefix":"10.1007","volume":"35","author":[{"given":"Junzhe","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharuka Beragama","family":"Vithanage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Gulewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hawau","family":"Abdulsalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hien M.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"3553_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/852093","volume":"2013","author":"AM Gomes","year":"2013","unstructured":"Gomes AM, Stelling MP, Pav\u00e3o MSG. Heparan sulfate and heparanase as modulators of breast cancer progression. Biomed Res Int. 2013;2013:852093. https:\/\/doi.org\/10.1155\/2013\/852093.","journal-title":"Biomed Res Int"},{"key":"3553_CR2","first-page":"4655","volume":"61","author":"A Koliopanos","year":"2001","unstructured":"Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 2001;61:4655\u20139.","journal-title":"Cancer Res"},{"key":"3553_CR3","doi-asserted-by":"crossref","unstructured":"Purushothaman A, Sanderson RD Heparanase: a dynamic promoter of myeloma progression. In: Vlodavsky I, Sanderson RD, Ilan N, editors. Heparanase: From Basic Research to Clinical Applications. Cham: Springer International Publishing; 2020. p. 331-49.","DOI":"10.1007\/978-3-030-34521-1_12"},{"key":"3553_CR4","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/1078-0432.Ccr-07-1866","volume":"14","author":"I Lerner","year":"2008","unstructured":"Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res. 2008;14:668\u201376. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1866.","journal-title":"Clin Cancer Res"},{"key":"3553_CR5","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/cncr.23680","volume":"113","author":"E Cohen","year":"2008","unstructured":"Cohen E, Doweck I, Naroditsky I, Ben-Izhak O, Kremer R, Best LA, et al. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer. 2008;113:1004\u201311. https:\/\/doi.org\/10.1002\/cncr.23680.","journal-title":"Cancer"},{"key":"3553_CR6","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/cells12141891","volume":"12","author":"V Manganelli","year":"2023","unstructured":"Manganelli V, Misasi R, Riitano G, Capozzi A, Mattei V, Caglar TR, et al. Role of a novel heparanase inhibitor on the balance between apoptosis and autophagy in U87 human glioblastoma cells. Cells. 2023;12:1891 https:\/\/doi.org\/10.3390\/cells12141891.","journal-title":"Cells"},{"key":"3553_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02624-1","volume":"18","author":"KM Jayatilleke","year":"2020","unstructured":"Jayatilleke KM, Hulett MD. Heparanase and the hallmarks of cancer. J Transl Med. 2020;18:453. https:\/\/doi.org\/10.1186\/s12967-020-02624-1.","journal-title":"J Transl Med"},{"key":"3553_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12307-011-0082-7","volume":"5","author":"I Vlodavsky","year":"2012","unstructured":"Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N, et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron. 2012;5:115\u201332. https:\/\/doi.org\/10.1007\/s12307-011-0082-7.","journal-title":"Cancer Microenviron"},{"key":"3553_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/1389557516666161101143643","volume":"17","author":"H Jin","year":"2017","unstructured":"Jin H, Zhou S. The functions of heparanase in human diseases. Mini-Reviews in Medicinal Chemistry. 2017;17:541\u20138. https:\/\/doi.org\/10.2174\/1389557516666161101143643.","journal-title":"Mini-Reviews in Medicinal Chemistry"},{"key":"3553_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1006\/scbi.2001.0420","volume":"12","author":"I Vlodavsky","year":"2002","unstructured":"Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol. 2002;12:121\u20139. https:\/\/doi.org\/10.1006\/scbi.2001.0420.","journal-title":"Semin Cancer Biol"},{"key":"3553_CR11","doi-asserted-by":"publisher","first-page":"M99","DOI":"10.1016\/S0304-419X(01)00017-8","volume":"1471","author":"CR Parish","year":"2001","unstructured":"Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2001;1471:M99\u2013M108. https:\/\/doi.org\/10.1016\/S0304-419X(01)00017-8.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer."},{"key":"3553_CR12","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1096\/fj.00-0895fje","volume":"15","author":"M Elkin","year":"2001","unstructured":"Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001;15:1661\u20133. https:\/\/doi.org\/10.1096\/fj.00-0895fje.","journal-title":"FASEB J"},{"key":"3553_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/2211-5463.12190","volume":"7","author":"T Batool","year":"2017","unstructured":"Batool T, Fang J, Barash U, Moustakas A, Vlodavsky I, Li J-P. Overexpression of heparanase attenuated TGF-\u03b2-stimulated signaling in tumor cells. FEBS Open Bio. 2017;7:405\u201313. https:\/\/doi.org\/10.1002\/2211-5463.12190.","journal-title":"FEBS Open Bio"},{"key":"3553_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1158\/0008-5472.Can-05-1811","volume":"66","author":"A Zetser","year":"2006","unstructured":"Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006;66:1455\u201363. https:\/\/doi.org\/10.1158\/0008-5472.Can-05-1811.","journal-title":"Cancer Res"},{"key":"3553_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/dvdy.24557","volume":"247","author":"G Tzanakakis","year":"2018","unstructured":"Tzanakakis G, Kavasi R-M, Voudouri K, Berdiaki A, Spyridaki I, Tsatsakis A, et al. Role of the extracellular matrix in cancer-associated epithelial to mesenchymal transition phenomenon. Dev Dyn. 2018;247:368\u201381. https:\/\/doi.org\/10.1002\/dvdy.24557.","journal-title":"Dev Dyn"},{"key":"3553_CR16","doi-asserted-by":"publisher","first-page":"5059","DOI":"10.1007\/s00018-020-03559-y","volume":"77","author":"R Koganti","year":"2020","unstructured":"Koganti R, Suryawanshi R, Shukla D. Heparanase, cell signaling, and viral infections. Cell Mol Life Sci. 2020;77:5059\u201377. https:\/\/doi.org\/10.1007\/s00018-020-03559-y.","journal-title":"Cell Mol Life Sci"},{"key":"3553_CR17","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/jcp.30995","volume":"238","author":"Y Yang","year":"2023","unstructured":"Yang Y, Yuan F, Zhou H, Quan J, Liu C, Wang Y, et al. Potential roles of heparanase in cancer therapy: Current trends and future direction. J Cell Physiol. 2023;238:896\u2013917. https:\/\/doi.org\/10.1002\/jcp.30995.","journal-title":"J Cell Physiol"},{"key":"3553_CR18","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/nsmb.3136","volume":"22","author":"L Wu","year":"2015","unstructured":"Wu L, Viola CM, Brzozowski AM, Davies GJ. Structural characterization of human heparanase reveals insights into substrate recognition. Nat Struct Mol Biol. 2015;22:1016\u201322. https:\/\/doi.org\/10.1038\/nsmb.3136.","journal-title":"Nat Struct Mol Biol"},{"key":"3553_CR19","doi-asserted-by":"crossref","unstructured":"Wu L, Davies GJ An overview of the structure, mechanism and specificity of human heparanase. In: Vlodavsky I, Sanderson RD, Ilan N, editors. Heparanase: From Basic Research to Clinical Applications. Cham: Springer International Publishing; 2020. p. 139-67.","DOI":"10.1007\/978-3-030-34521-1_5"},{"key":"3553_CR20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/nchembio.1956","volume":"11","author":"L Bohlmann","year":"2015","unstructured":"Bohlmann L, Tredwell GD, Yu X, Chang C-W, Haselhorst T, Winger M, et al. Functional and structural characterization of a heparanase. Nat Chem Biol. 2015;11:955\u20137. https:\/\/doi.org\/10.1038\/nchembio.1956.","journal-title":"Nat Chem Biol"},{"key":"3553_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fonc.2014.00195","volume":"4","author":"E Hammond","year":"2014","unstructured":"Hammond E, Khurana A, Shridhar V, Dredge K. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol. 2014;4:195 https:\/\/doi.org\/10.3389\/fonc.2014.00195.","journal-title":"Front Oncol"},{"key":"3553_CR22","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/S0049-3848(07)70139-1","volume":"120","author":"I Vlodavsky","year":"2007","unstructured":"Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz B-Z, Naggi A, et al. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res. 2007;120:S112\u2013S20. https:\/\/doi.org\/10.1016\/S0049-3848(07)70139-1.","journal-title":"Thromb Res"},{"key":"3553_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1160\/TH09-02-0091","volume":"102","author":"J-p Li","year":"2009","unstructured":"Li J-p, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost. 2009;102:823\u20138. https:\/\/doi.org\/10.1160\/TH09-02-0091.","journal-title":"Thromb Haemost"},{"key":"3553_CR24","doi-asserted-by":"publisher","first-page":"e21106","DOI":"10.1371\/journal.pone.0021106","volume":"6","author":"H Zhou","year":"2011","unstructured":"Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One. 2011;6:e21106 https:\/\/doi.org\/10.1371\/journal.pone.0021106.","journal-title":"PLoS One"},{"key":"3553_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3466.2004.tb00127.x","volume":"22","author":"LM Khachigian","year":"2004","unstructured":"Khachigian LM, Parish CR. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies. Cardiovasc Drug Rev. 2004;22:1\u20136. https:\/\/doi.org\/10.1111\/j.1527-3466.2004.tb00127.x.","journal-title":"Cardiovasc Drug Rev"},{"key":"3553_CR26","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/1078-0432.Ccr-10-2476","volume":"17","author":"JP Ritchie","year":"2011","unstructured":"Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase\/syndecan-1 axis. Clin Cancer Res. 2011;17:1382\u201393. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2476.","journal-title":"Clin Cancer Res"},{"key":"3553_CR27","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.2174\/138161207781039742","volume":"13","author":"I Vlodavsky","year":"2007","unstructured":"Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 2007;13:2057\u201373. https:\/\/doi.org\/10.2174\/138161207781039742.","journal-title":"Curr Pharm Des"},{"key":"3553_CR28","doi-asserted-by":"publisher","first-page":"12058","DOI":"10.1021\/acs.jmedchem.5c00937","volume":"68","author":"H Abdulsalam","year":"2025","unstructured":"Abdulsalam H, Philip L, Singh K, Farhoud M, Ilan N, Vlodavsky I, et al. Design of paromomycin and neomycin as sulfated and hydrophobic glycans to target heparanase-driven tumor progression and metastasis. J Med Chem. 2025;68:12058\u201384. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00937.","journal-title":"J Med Chem"},{"key":"3553_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117792","volume":"295","author":"L Philip","year":"2025","unstructured":"Philip L, Abdulsalam H, Singh K, Nguyen H. Investigation into the binding domains of platelet factor 4 unlocks new avenues for the design and synthesis of selective pseudo-tetrasaccharide heparanase-inhibiting heparan sulfates. Eur J Med Chem. 2025;295:117792. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117792.","journal-title":"Eur J Med Chem"},{"key":"3553_CR30","doi-asserted-by":"publisher","first-page":"6899","DOI":"10.1021\/acs.jcim.5c00371","volume":"65","author":"H Abdulsalam","year":"2025","unstructured":"Abdulsalam H, Hix MA, Philip L, Singh K, Walker AR, Nguyen HM. From docking and molecular dynamics to experimental discovery: exploring the hydrophobic landscapes of heparanase to design potent inhibitors. J Chem Inf Model. 2025;65:6899\u2013912. https:\/\/doi.org\/10.1021\/acs.jcim.5c00371.","journal-title":"J Chem Inf Model"},{"key":"3553_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202304325","volume":"135","author":"J Wakpal","year":"2023","unstructured":"Wakpal J, Pathiranage V, Walker AR, Nguyen HM. Rational design and expedient synthesis of heparan sulfate mimetics from natural aminoglycosides for structure and activity relationship studies. Angew Chem Int Ed. 2023;135:e202304325. https:\/\/doi.org\/10.1002\/anie.202304325.","journal-title":"Angew Chem Int Ed"},{"key":"3553_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev-biochem-030222-120000","volume":"93","author":"JM Paggi","year":"2024","unstructured":"Paggi JM, Pandit A, Dror RO. The art and science of molecular docking. Annu Rev Biochem. 2024;93:389\u2013410. https:\/\/doi.org\/10.1146\/annurev-biochem-030222-120000.","journal-title":"Annu Rev Biochem"},{"key":"3553_CR33","first-page":"1024","volume":"4","author":"S Agarwal","year":"2016","unstructured":"Agarwal S, Mehrotra R. An overview of molecular docking. JSM chem. 2016;4:1024\u20138.","journal-title":"JSM chem"},{"key":"3553_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.51847\/Une9jqjUCl","volume":"13","author":"MK Sahu","year":"2024","unstructured":"Sahu MK, Nayak AK, Hailemeskel B, Eyupoglu OE. Exploring recent updates on molecular docking: Types, method, application, limitation & future prospects. International Journal of Pharmaceutical Research and Allied Sciences. 2024;13:24\u201340. https:\/\/doi.org\/10.51847\/Une9jqjUCl.","journal-title":"International Journal of Pharmaceutical Research and Allied Sciences"},{"key":"3553_CR35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2174\/1389450119666181022153016","volume":"20","author":"S Saikia","year":"2019","unstructured":"Saikia S, Bordoloi M. Molecular docking: challenges, advances and its use in drug discovery perspective. Curr Drug Targets. 2019;20:501\u201321. https:\/\/doi.org\/10.2174\/1389450119666181022153016.","journal-title":"Curr Drug Targets"},{"key":"3553_CR36","doi-asserted-by":"crossref","unstructured":"Ghasemi JB, Abdolmaleki A, Shiri F Molecular docking challenges and limitations. Pharmaceutical sciences: Breakthroughs in research and practice. IGI Global Scientific Publishing; 2017. p. 770-94.","DOI":"10.4018\/978-1-5225-1762-7.ch030"},{"key":"3553_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/156802610790232260","volume":"10","author":"J Verma","year":"2010","unstructured":"Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design-a review. Curr Top Med Chem. 2010;10:95\u2013115.","journal-title":"Curr Top Med Chem"},{"key":"3553_CR38","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2174\/1568026023392887","volume":"2","author":"M Akamatsu","year":"2002","unstructured":"Akamatsu M. Current state and perspectives of 3D-QSAR. Curr Top Med Chem. 2002;2:1381\u201394.","journal-title":"Curr Top Med Chem"},{"key":"3553_CR39","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1359-6446(97)01079-9","volume":"2","author":"H Kubinyi","year":"1997","unstructured":"Kubinyi H. QSAR and 3D QSAR in drug design Part 1: methodology. Drug Discov Today. 1997;2:457\u201367.","journal-title":"Drug Discov Today"},{"key":"3553_CR40","doi-asserted-by":"crossref","unstructured":"Vrbanac J, Slauter R ADME in drug discovery. A comprehensive guide to toxicology in nonclinical drug development. Elsevier; 2017. p. 39-67.","DOI":"10.1016\/B978-0-12-803620-4.00003-7"},{"key":"3553_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/s1359-6446(00)01540-3","volume":"5","author":"PJ Eddershaw","year":"2000","unstructured":"Eddershaw PJ, Beresford AP, Bayliss MK. ADME\/PK as part of a rational approach to drug discovery. Drug Discov Today. 2000;5:409\u201314. https:\/\/doi.org\/10.1016\/s1359-6446(00)01540-3.","journal-title":"Drug Discov Today"},{"key":"3553_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2174\/1389200222666210705122913","volume":"22","author":"NE-H Daoud","year":"2021","unstructured":"Daoud NE-H, Borah P, Deb PK, Venugopala KN, Hourani W, Alzweiri M, et al. ADMET profiling in drug discovery and development: perspectives of in silico, in vitro and integrated approaches. Curr Drug Metab. 2021;22:503\u201322. https:\/\/doi.org\/10.2174\/1389200222666210705122913.","journal-title":"Curr Drug Metab"},{"key":"3553_CR43","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2174\/15680266113139990033","volume":"13","author":"F Cheng","year":"2013","unstructured":"Cheng F, Li W, Liu G, Tang Y. In silico ADMET prediction: recent advances, current challenges and future trends. Curr Top Med Chem. 2013;13:1273\u201389. https:\/\/doi.org\/10.2174\/15680266113139990033.","journal-title":"Curr Top Med Chem"},{"key":"3553_CR44","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1021\/acs.biochem.5b00079","volume":"54","author":"IG Denisov","year":"2015","unstructured":"Denisov IG, Grinkova YV, Baylon JL, Tajkhorshid E, Sligar SG. Mechanism of drug\u2013drug interactions mediated by human cytochrome P450 CYP3A4 monomer. Biochemistry. 2015;54:2227\u201339. https:\/\/doi.org\/10.1021\/acs.biochem.5b00079.","journal-title":"Biochemistry"},{"key":"3553_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41\u201357. https:\/\/doi.org\/10.2165\/00003088-200038010-00003.","journal-title":"Clin Pharmacokinet"},{"key":"3553_CR46","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391\u20136.","journal-title":"Am Fam Physician"},{"key":"3553_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/dmd.105.005785","volume":"34","author":"TM Cho","year":"2006","unstructured":"Cho TM, Rose RL, Hodgson E. In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes. Drug Metab Dispos. 2006;34:176\u201383. https:\/\/doi.org\/10.1124\/dmd.105.005785.","journal-title":"Drug Metab Dispos"},{"key":"3553_CR48","first-page":"3742","volume":"11","author":"E Mohiuddin","year":"2021","unstructured":"Mohiuddin E, Wakimoto H. Extracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches. Am J Cancer Res. 2021;11:3742\u201354.","journal-title":"Am J Cancer Res"},{"key":"3553_CR49","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3390\/cancers15061879","volume":"15","author":"S Marino","year":"2023","unstructured":"Marino S, Menna G, Di Bonaventura R, Lisi L, Mattogno P, Fig\u00e0 F, et al. The extracellular matrix in glioblastomas: a glance at its structural modifications in shaping the tumoral microenvironment\u2014a systematic review. Cancers. 2023;15:1879 https:\/\/doi.org\/10.3390\/cancers15061879.","journal-title":"Cancers"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03553-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03553-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03553-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:27:49Z","timestamp":1777458469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03553-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03553-2","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}